Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.

The conversation is about finding a legitimate source for RU58841 in Germany, with suggestions including Receptorchem and GeneTherica. Anageninc and Chemyo do not deliver to Germany.

Epristeride is a selective 5 alpha reductase type 2 inhibitor that may reduce scalp DHT similarly to finasteride, with potentially fewer side effects. It is suggested that combining epristeride with finasteride or dutasteride could enhance hair loss treatment effectiveness.

A user has used finasteride for three years to maintain hair thickness and is considering adding minoxidil for temple recession. They report no side effects and are satisfied, while others discuss minoxidil's pros and cons and share hair treatment experiences.

The user applies a topical solution containing minoxidil, finasteride, dutasteride, retinoic acid, and hydrocortisone to address scalp inflammation and is considering adding cetirizine to the mix. They are calculating the correct amount of cetirizine to add to their formula and have paused this approach to retry oral minoxidil.

17-alpha-estradiol may work for hair loss by inhibiting 5-alpha reductase, similar to finasteride. It might lower testosterone in the scalp, reducing DHT conversion.

Low folic acid may worsen side effects of finasteride. Consult a doctor for personalized advice.

The user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and ask for advice on shipping within the EU and product quality, while also mentioning their current hair loss treatment involves mixing RU with Stemoxydine and Alfatradiol.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

The user is three months into using topical finasteride, minoxidil, and tretinoin for hair loss, noticing slight improvement in hair density. They plan to continue treatment and expect more visible results between 6 to 9 months, with the goal of stabilizing hair loss and possibly achieving some regrowth.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.

The user experienced significant hair regrowth in three months using 1mg finasteride three days a week and topical minoxidil daily, with initial side effects from finasteride that resolved after adjusting the dosage. They used liquid minoxidil from the Kirkland brand and initially included microneedling in their routine.

The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.

A user in the UK reports significant hair growth progress after three months using a topical spray containing Minoxidil, Finasteride, and Tretinoin, applied daily. They recommend the product from e-Surgery, noting no side effects and using Biotin shampoo every two days.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.

The conversation is about whether an EAA supplement affects hair health. The user lists the ingredients but does not receive a definitive answer.

The user reports good progress in hair growth after three months using finasteride, minoxidil with tretinoin, Alpecin C1, biotin, vitamin D3, iron, zinc, omega-3, and microneedling with rosemary/mint oil. Other users note initial shedding and discuss areas where hair growth is less effective.

An 18-year-old is using minoxidil, finasteride, and tretinoin for hair loss, with concerns about uneven temple progress. They have been on minoxidil for 3.5 months and finasteride for 2 months.

A user asked if taking a blood test 3 days after starting finasteride would affect the results for Estradiol, FSH, SHBG, Progesterone, and DHEA-S. The conversation is about the timing of blood tests after beginning finasteride treatment.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

A user is considering a 3-in-1 capsule containing Finasteride, Minoxidil, and Biotin for hair loss. Concerns are raised about Biotin's impact on the effectiveness of Finasteride and Minoxidil, and the cost is unclear without logging in.

The user reports progress in treating hair loss using oral minoxidil, finasteride, topical RU58841, a derma stamp, and ketoconazole shampoo. They experience no side effects from RU58841 and believe it acts locally.

Calecim (PTT-6) Advanced Hair System is a 6-week hair restoration product using stem cell-derived ingredients to stimulate hair growth. Users are skeptical, calling it overpriced and ineffective, suggesting alternatives like LLLT devices or PRP treatments.

GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.

Finasteride can cause initial hair shedding, which may indicate effectiveness, with improvements seen after 12-24 months. Some users enhance results by combining it with minoxidil and dermarolling.

The user reported slight hair improvement after three months using a DIY topical mix of crushed finasteride tablets and minoxidil solution. They are hoping for more coverage, especially on the crown, despite starting treatment late.

A 19-year-old is using topical minoxidil 7% and finasteride 0.1% foam, along with a laser cap, to combat hair loss. They report progress despite initial shedding and are considering switching to oral finasteride in the future for convenience.

The user experienced significant hair regrowth by returning to a regimen of 1mg oral finasteride daily and daily topical minoxidil after previously reducing their doses. They also emphasize maintaining energy and health through diet, exercise, and supplements.

The conversation discusses hair loss treatments, including finasteride, minoxidil, estradiol, and spironolactone, with a focus on their effects on hair regrowth and gender transition. The original poster shares their personal experience with these treatments, emphasizing that estradiol and spironolactone should not be used by those who want to maintain a masculine appearance.